Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Last year it was December 7.
Avid Bioservices Appoints Oksana Lukash as Vice President, People
November 16 2022 - 08:05AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries.
Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year tenure with the company, she was instrumental in driving three acquisitions and the successful integration of the acquired entities. Ms. Lukash is also credited with growing Oncocyte’s employee base by nearly 600%, with less than 5% turnover and securing recognition for the company multiple times as a “Best Places to Work” locally and national. Throughout her career, she has also held senior human resources roles with several other leading life science companies including Avanir Pharmaceuticals, Agendia, and Clarient. Ms. Lukash is also an active member of Chief network, a private network built to drive more women into positions of leadership, as well as a vice chair of the board for the Dee Dee Jackson Foundation, an organization that connects those who have a commonality in grief.
“We are excited to welcome Oksana and her track record of successfully building and supporting workforces and creating best-in-breed cultures at a range of leading companies within the life science industry to Avid,” said Nick Green, president and chief executive officer of Avid Bioservices. “Her strategic, tech-savvy approach is an ideal fit for the company and we look forward to the contributions that she will make in continuing to enhance our team and optimize the workplace in which they drive Avid’s success.”
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
Yes. NASDAQ WAS 100.35 previously.
According to Fintel
Institutional Shares (Long) 74,746,917 - 120.23% (ex 13D/G)
According to NASDAQ
Institutional Ownership 104.10%
T Rowe Price new position
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. 09/30/2022 1,642,093 1,642,093 New $25,223
I totally agree with you.
FMR LLC (Fidelity) has greatly reduced their position.
FMR LLC 06/30/2022 6,088,025
New 13G filed showing 2,978,979 shares owned.
Institutional investment 116.69% now.
https://fintel.io/so/us/cdmo
HALO up over $4.
The usual premarket games. Down .67 on 5 shares.
HALO had excellent results up 1.37 AH.
Third Quarter Revenue Increased 80% YOY to $209 Million, with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.741
Record Third Quarter Royalty Revenue Increased 70% YOY to $99.6 Million
Reiterating 2022 Revenue Guidance of $655 Million to $685 Million, Representing 48%-55% Growth over Reported 2021 Revenue
Another source:
Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.23, revenue of $208.98M beats by $17.81M
It was from Friday, at 3:25pm. Reg SHO list
CDMO,"Avid Bioservices, Inc.",R,11/4/2022 3:25:04 PM
I just saw the tweet and posted it, but it doesn’t appear that CDMO dropped 10% today for the circuit breaker to kick in. Therefore, the tweet and my prior post may be in error.
AVID BIOSERVICES INC - CDMO
Short sale restricted for 2022-11-07
FWIW, I bought some at 12.99. Nick and the boys should make some open market purchases here.
Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference
November 02 2022 - 04:05PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will deliver a corporate presentation at the conference, which will take place November 7-10, 2022, in Rancho Palos Verdes, CA.
Details of the company’s participation are as follows:
Credit Suisse 31st Annual Healthcare Conference
Conference Date: November 7-10, 2022
Presentation Time/Date: 12:50 - 1:20 p.m. Pacific on Wednesday, November 9, 2022
Location: Terranea Resort, Rancho Palos Verdes, CA
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Fintel has institutional investment at 115.48% up From 113.86% earlier today.
Jennison Associates increased their ownership 53%, totaling 2.877 mil shares.
Another
10/31/2022 11:00:36 EDT F 17.02 299604 NDD
Large red trade
10/31/2022 10:40:13 EDT F 17.00 359619 NDD
Avid Bioservices Inc
NASDAQ
17.73 0.61 (3.56%)
Oct 28, 2022, 3:59:54 PM EDT
Day's Range N/A - N/A
52 Week Range 11.30 - 34.51
Pharmaceutical Preparatio...
Short Interest shares - source: NASDAQ
Short Interest Ratio 9.10 Days to Cover
Short Interest % Float 7.87% - source: NASDAQ (short interest), Capital IQ (float)
Off-Exchange Short Volume 46,741 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 69.27% - source: FINRA (inc. Dark Pool volume)
Off exchange short volume up from 63+% yesterday
Short Interest Ratio 7.23 Days to Cover
Short Interest % Float 7.87% - source: NASDAQ (short interest), Capital IQ (float)
Off-Exchange Short Volume 141,092 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 63.23% - source: FINRA (inc. Dark Pool volume)
From Fintel.io
Short Interest Ratio 6.80 Days to Cover
Short Interest % Float 8.83% - source: NASDAQ (short interest), Capital IQ (float)
Off-Exchange Short Volume 85,622 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 21.81% - source: FINRA (inc. Dark Pool volume)
Nah. No credits for stupidity.
As of 9/30 it was 8.83% according to TDAmeritrade. Quite a jump. Seems like someone is buying in?
And yet, still more buying than selling. 75K vs 68 K.
Buy volume 296K sell volume 295K
https://ih.advfn.com/stock-market/NASDAQ/avid-bioservices-CDMO/trades
TOMI to Install Custom Engineered Integrated iHP System in Avid Bioservices, Inc. Viral Vector Manufacturing Facility in California
October 10 2022 - 08:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP), today announced that it has recently received a purchase order for an iHP Custom Engineered System (CES) from Avid Bioservices, Inc. (Avid) for implementation in Avid’s new purpose-built viral vector development and manufacturing facility in Costa Mesa, California.
Avid is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. With the rapidly growing cell and gene therapy market, Avid is constructing a 53,000 square foot world-class CGMP manufacturing building dedicated to viral vector development and manufacturing. SteraMist has been chosen by Avid as its preferred decontamination method due to SteraMist’s ability to rapidly decontaminate and disinfect the area approximately four times faster than the competition, and its low percentage (7.8%) hydrogen peroxide BIT solution that provides superior material compatibility on surfaces.
During site development, a SteraMist iHP Custom Engineered System will be implemented within four (4) GMP manufacturing suites. This will require eleven (11) applicators with a single control panel and a 55-gallon BIT solution container. Earlier this month, the TOMI team began working with Avid’s team on planning the installation, which is projected to be finalized in the first half of 2023.
Atef Khezri, executive director of viral vector manufacturing at Avid Bioservices, said, “Our team at Avid looks forward to working with TOMI on the installation of the custom decontamination system. With the need for an effective and robust decontamination system to provide a sterile environment and a quick turnaround time, SteraMist was the evident solution.”
“The TOMI team put forth a great effort to win this bid. Avid conducted extensive due diligence which we were able to report successfully,” Elissa J. (E.J.) Shane, Chief Operating Officer at TOMI states. “We are well prepared for this project and eager to work with another innovative company for a seamless install of an iHP Custom Engineered System. TOMI looks forward to future opportunities to expand SteraMist throughout other areas of the facility.”
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ: CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to anticipated financial performance and operating results, including result for the March quarter in 2022; expected growth in sales and market demand; intent to sell shares by the management; revenue opportunities of CES products and timing of revenue recognition; growth strategies of the company; anticipated manufacturing capability; and trading price of common stock. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Jennifer Belodeau
IMS Investor Relations
tomi@imsinvestorrelations.com
Primary Logo
Poor cf. nothing to gloat about today.
2 trades premarket
Date/Time Price Shares Exch/Mkt
10/03/2022 8:01:23 EDT I 20.45 4 CBOE EDGX
10/03/2022 7:44:45 EDT W 19.12 1610
10:44:28 $ 19.81 120,000
Will we see higher volume due to quarter end adjustments?
Avid Bioservices to Participate in RBC Global CDMO Conference
September 27 2022 - 04:05PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Global CDMO Conference. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place October 3-4, 2022.
Details of the company’s participation are as follows:
RBC Global CDMO Conference
Conference Date: October 3-4, 2022
Fireside Chat Time/Date: 12:15 - 12:45 p.m. Eastern on Monday, October 3, 2022
Format: Virtual conference; webcast available
To listen to the webcast of the RBC fireside chat please visit: http://ir.avidbio.com/investor-events.
Agreed.
Higher than normal volume today.
Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations
September 22, 2022 at 8:05 AM EDT
Download PDF
Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility Expansion Projects
TUSTIN, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Michael Alston, Jr. as vice president, operations. Mr. Alston was promoted from Avid’s director of project engineering, a role in which he led all of the company’s ongoing facility expansions. In his new position, he will continue to oversee these projects including the Myford South expansion, as well as the construction of Avid’s new dedicated cell and gene therapy facility.
Mr. Alston has more than 15 years of experience spanning operational and capital management responsibilities supporting cGMP manufacturing, facilities, engineering, and environmental, health and safety (EHS) functions. Prior to joining Avid in 2019, Mr. Alston was associate director, engineering and facilities with Sterogene Bioseperations, where he led the biotechnology company’s engineering, facilities, maintenance, safety and environmental functions. During this time, he led the design, construction and launch of Sterogene’s new, more than $5 million cGMP laboratory and pilot plant manufacturing facility. Mr. Alston has also previously served in senior roles within Merck’s viral vaccine manufacturing unit, including senior manufacturing supervisor. His career has included senior engineering, facilities and operational management positions with Unilever and ConAgra Foods.
“Michael’s promotion to vice president, operations, is well deserved based on the exceptional job he has done leading and overseeing our multiple facility expansion and buildout projects, which are complex and occurring concurrently. His extensive background in both engineering and operations is ideally suited for his new role and the responsibilities that come with the position. We are thrilled to be able to promote such a talented individual from within Avid to this key role and look forward to Michael’s continued contributions to the company’s success,” said Nick Green, president and chief executive officer of Avid Bioservices.
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
RBC Capital Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
In a report released on September 16, Sean Dodge from RBC Capital maintained a Buy rating on Avid Bioservices (CDMO – Research Report), with a price target of $22.00. The company’s shares closed yesterday at $17.15.
Dodge covers the Technology sector, focusing on stocks such as Signify Health, OptimizeRx, and GoodRx Holdings. According to TipRanks, Dodge has an average return of -2.4% and a 45.03% success rate on recommended stocks.
Avid Bioservices has an analyst consensus of Moderate Buy, with a price target consensus of $22.00.
See Insiders’ Hot Stocks on TipRanks >>
CDMO market cap is currently $1.06B and has a P/E ratio of 9.72.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CDMO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avid Bioservices, Inc. engages in the commercial manufacturing which focuses on biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. The firm specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions, and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.
Buy vol 938K vs. 350K sell
https://ih.advfn.com/stock-market/NASDAQ/avid-bioservices-CDMO/trades
Buy volume 173K sell 123K
Anyone listen to the Morgan Stanley presentation today?
Since we are attending the Morgan Stanley HC Conf, maybe they will put out a rec like they did for HALO this morning:
Morgan Stanley suggests that investors who are looking for safety in a volatile market might consider investing in this biotechnology stock. Andrew Galler, analyst at Morgan Stanley, began coverage of Halozyme Therapeutics. The company was given an overweight rating and a price target of $50. Galler described the company as a “safe port” in a storm. He wrote that Halozyme was the most defensive name we covered due to its established royalty business, long term potential for growth and diversified base business through its acquisition of Antares. Galler specifically sees value and diversification in Halozyme’s revenue streams. He emphasized Enhanze’s drug delivery technology platform. This platform is being used by major biopharmaceutical companies such as Pfizer and Bristol-Myers Squibb. Morgan Stanley’s $50 price target indicates that shares could rise 26% after Thursday’s close. He wrote that “While we don’t see any significant upside drivers other than continued expansion of Enhanze portfolio, and commercial executions by partners in near-term”, he said. — CNBC’s Michael Bloom contributed to this report.”
For 1 share.
According to Seeking Alpha:
Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M
Sep. 06, 2022 4:20 PM ETAvid Bioservices, Inc. (CDMO)By: Dania Nadeem, SA News Editor
Avid Bioservices press release (NASDAQ:CDMO): Q1 GAAP EPS of $0.02 beats by $0.01.
Revenue of $36.7M (+19.3% Y/Y) beats by $3.26M.
Shares -1.6%.